Hostname: page-component-6898cfcb55-cbk24 Total loading time: 0 Render date: 2026-11-11T03:25:29.814Z Has data issue: false hasContentIssue false
  • English
  • Français

Cognitive Impairment in Schizophrenia

Published online by Cambridge University Press:  07 November 2014

Philip D. Harvey
Get accessRights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Clinical Information Monograph
Information
CNS Spectrums , Volume 10 , Issue 2 , February 2005, pp. 7 - 9
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.Hegarty, JD, Baldessarini, RJ, Tohen, M, Waternaux, C, Oepen, G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151(10):1409–1416.Google ScholarPubMed
2.Harvey, PD, Keefe, RSE. Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment. CNS Spectr. 1997;2(8):41–53.Google Scholar
3.Green, MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321–330.Google Scholar
4.Green, MF, Kern, RS, Braff, DL, et al.Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull. 2000;26:119–136.CrossRefGoogle ScholarPubMed
5.McGurk, SR, Meltzer, HY. The role of cognition in vocational functioning in schizophrenia. Schizophr Res. 2000;45(3):175–184.Google Scholar
6.Cornblatt, BA, Keilp, JG. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull. 1994;20:31–46.Google Scholar
7.Harvey, PD, Howanitz, E, Parrella, M, et al.Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry. 1998;155:1080–1086.CrossRefGoogle ScholarPubMed
8.Callicott, JH, Bertolino, A, Mattay, VS, et al.Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex. 2000; 10:1078–1092.CrossRefGoogle ScholarPubMed
9.Egan, MF, Straub, RE, Goldberg, TE,, et al.Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. PANAS. 2004;101:12604–12609.Google Scholar
10.Joseph, I. Friedman, , Adler, DN, Howanitz, E, et al.A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry. 2002;51:349–357.Google Scholar
11.Harvey, PD, Keefe, RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158:176–184.Google Scholar
12.Harvey, PD, Green, MF, Meltzer, HY, et al.The cognitive effects of risperidone and olanzapine in patients with schizoaffective disorder or schizophrenia. Psychopharmacology. 2003;169:404–411.Google Scholar
13.Purdon, SE, Jones, BD, Stip, E, et al.Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry. 2000;57:249–258.Google Scholar
14.Bilder, RM, Goldman, RS, Volavka, J, et al.Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159:1018–1028.CrossRefGoogle ScholarPubMed
15.Harvey, PD, Meltzer, HY, Simpson, GM, et al.Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res. 2004;66:101–114.Google Scholar
16.Weiden, P, Simpson, G, Potkin, S, et al.Switching to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in stable outpatients with schizophrenia. J Clin Psychiatry. 2003;64:580–588.Google Scholar
17.Harvey, PD, Bowie, CR, Loebel, A. Neuropsychological normalization with 6 months treatments with atypical antipsychotic medications. J Neuropsych Clin Neurosci. In press.Google Scholar
18.Bertolino, A, Caforio, G, Blasi, G, et al.Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry. 2004;161:1798–1805.Google Scholar
19.Harvey, PD, Green, MF, Keefe, RSE, et al.Cognitive function in schizophrenia: Its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry. 2004;65:361–372.Google Scholar